Elevated expression of CX3C chemokine receptor 1 mediates recruitment of T cells into bone marrow of patients with acquired aplastic anaemia

Journal of Internal Medicine

Volumn 276, Issue 5, 2014, Pages 512-524

  Ren, J ^a,b   Hou, X Y ^a   Ma, S H ^c   Zhang, F K ^c   Zhen, J H ^d   Sun, L ^a   Sun, Y X ^a   Hao, Y L ^e   Cheng, Y F ^f   Hou, M ^a,g   Xu, C G ^a   Zhang, M H ^a   Peng, J ^a  

^a SHANDONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d SHANDONG UNIVERSITY   (China)

^e Department of Pathology   (China)

^f FUDAN UNIVERSITY   (China)

^g BEIJING HOSPITAL   (China)

Author keywords

Aplastic anaemia; CX3C chemokine receptor 1; T cells; Very late activation antigen 4

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; CYCLOSPORIN; FRACTALKINE; LIGAND; THYMOCYTE ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ACQUIRED APLASTIC ANAEMIA; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; PROTEIN EXPRESSION; T LYMPHOCYTE; ANEMIA, APLASTIC; BLOOD; CELL ADHESION; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS; PROSPECTIVE STUDY;

ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; BONE MARROW; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CHEMOTAXIS, LEUKOCYTE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTEGRIN ALPHA4BETA1; PROSPECTIVE STUDIES; RECEPTORS, CHEMOKINE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84911391852     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12218     Document Type: Article

References (35)

1. Young NS. Acquired aplastic anemia. Ann Intern Med 2002; 136: 534-546.
2. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008; 15: 162-168.
3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-2519.
4. Nakao S, Feng X, Sugimori C. Immune pathophysiology of aplastic anemia. Int J Hematol 2005; 82: 196-200.
5. Maciejewski JP, Risitano A, Kook H et al. Immune pathophysiology of aplastic anemia. Int J Hematol 2002; 76(Suppl 1): 207-214.
6. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995; 57: 827-872.
7. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66.
8. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12: 336-341.
9. Olsson B, Ridell B, Carlsson L et al. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008; 112: 1078-1084.
10. Hemler ME, Elices MJ, Parker C et al. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol Rev 1990; 114: 45-65.
11. Lobb RR, Hemler ME. The pathophysiologic role of α4 integrins in vivo. J Clin Invest 1994; 94: 1722-1728.
12. Hyun YM, Chung HL, McGrath JL et al. Activated integrin VLA-4 localizes to the lamellipodia and mediates T cell migration on VCAM-1. J Immunol 2009; 183: 359-369.
13. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
14. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
15. Laffón A, García-Vicuña R, Humbría A et al. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest 1991; 88: 546-552.
16. Ito Y, Kawachi H, Morioka Y et al. Fractalkine expression and the recruitment of CX3CR1 + cells in the prolonged mesangial proliferative glomerulonephritis. Kidney Int 2002; 61: 2044-2057.
17. Blaschke S, Koziolek M, Schwarz A et al. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol 2003; 30: 1918-1927.
18. Bjerkeli V, Damås JK, Fevang B et al. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis possible role in vascular inflammation. Rheumatology 2007; 46: 1422-1427.
19. Yajima N, Kasama T, Isozaki T et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005; 52: 1670-1675.
20. Camitta BM, Thomas ED, Nathan DG et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48: 63-70.
21. Rosenfeld S, Follmann D, Nunez O et al. Antithymocyte globulin and cyclosporine for Severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003; 289: 1130-1135.
22. Scheinberg P, Nunez O, Weinstein B et al. Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. N Engl J Med 2011; 365: 430-438.
23. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006; 133: 622-627.
24. Damås JK, Boullier A, Waehre T et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005; 25: 2567-2572.
25. Inoue A, Hasegawa H, Kohno M et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005; 52: 1522-1533.
26. Dorgham K, Ghadiri A, Hermand P et al. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 2009; 86: 903-911.
27. Maciejewski JP, Hibbs JP, Anderson S et al. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol 1994; 22: 1102-1110.
28. Mlenhorst JJ, Van Krieken JH, Dreef E et al. T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anaemia. Br J Haematol 1997; 99: 517-519.
29. Xin H, Kikuchi T, Andarini S et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005; 35: 1371-1380.
30. Fong AM, Robinson LA, Steeber DA et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion and activation under physiologic flow. J Exp Med 1998; 188: 1413-1419.
31. Kanazawa N, Nakamura T, Tashiro K et al. Fractalkine and macrophage-derived chemokine: T cell-attracting chemokines expressed in T cell area dendritic cells. Eur J Immunol 1999; 29: 1925-1932.
32. Umehara H, Bloom ET, Okazaki T et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34-40.
33. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-242.
34. Fraticelli P, Sironi M, Bianchi G et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107: 1173-1181.
35. Yoneda O, Imai T, Nishimura M et al. Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur J Immunol 2003; 33: 53-58.